EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a ‘living document’ and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available.

[1]  Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) , 2020, Chinese Medical Journal.

[2]  Q. Bassat,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[3]  G. FitzGerald.  Misguided drug advice for COVID-19 , 2020, Science.

[4]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[5]  L Rampal,et al.  Coronavirus disease (COVID-19) pandemic. , 2020, The Medical journal of Malaysia.

[6]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[7]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[8]  M. Dougados,et al.  2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2019, Annals of the rheumatic diseases.

[9]  F. Wolfe,et al.  Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study , 2019, RMD Open.

[10]  Mikiko Senga,et al.  Middle East Respiratory Syndrome. , 2017, The New England journal of medicine.

[11]  P. Merkel,et al.  EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis , 2016, Annals of the rheumatic diseases.

[12]  M. Dougados,et al.  2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations , 2014, Annals of the rheumatic diseases.

[13]  G. Hejblum,et al.  Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.

[14]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[15]  D. Ray,et al.  EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases , 2013, Annals of the rheumatic diseases.

[16]  J. Ioannidis,et al.  EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2010, Annals of the rheumatic diseases.

[17]  M. Falagas,et al.  Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review , 2007, Clinical Rheumatology.